Fresh Tracks Therapeutics, Inc. (FRTX)

OTCMKTS: FRTX · Delayed Price · USD
0.905
+0.004 (0.50%)
Mar 28, 2024, 2:12 PM EDT - Market closed

Company Description

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.

The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors.

Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022.

Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Fresh Tracks Therapeutics, Inc.
Fresh Tracks Therapeutics logo
Country United States
Founded 2009
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Albert Nicholas Marchio II

Contact Details

Address:
5777 Central Avenue, Suite 102
Boulder, Colorado 80301
United States
Phone (720) 505-4755
Website frtx.com

Stock Details

Ticker Symbol FRTX
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000819050
ISIN Number AU000000ELD6
Employer ID 93-0948554
SIC Code 2836

Key Executives

Name Position
Albert Nicholas Marchio II Chief Executive Officer, Chief Financial Officer, Secretary and Chairman
Aron Aizenstat M.B.A., P.M.P. Vice President of Corporate Development and Operations
Sue Fattor Head of Human Resource
Dr. James S. McElvain Ph.D. Interim Head of CMC Development

Latest SEC Filings

Date Type Title
Mar 18, 2024 15-12G Securities registration termination
Mar 15, 2024 10-K Annual Report
Mar 7, 2024 8-K Current Report
Feb 16, 2024 8-K Current Report
Feb 14, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 17, 2024 DEF 14A Other definitive proxy statements
Jan 17, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 5, 2024 PRE 14A Other preliminary proxy statements
Jan 3, 2024 8-K Current Report